Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues

PHASE4UnknownINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
Acromegaly
Interventions
DRUG

Sandostatin (Octreotide Acetate)

"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~* Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -\> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~* Frequency: every 4 weeks.~* Route of administration: IM injection."

Trial Locations (1)

138-736

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Novartis Korea Ltd.

INDUSTRY

lead

Asan Medical Center

OTHER